Microcap Ledger Tessera Defense & Homeland Security Inc. $HLSQ
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- NYSE American
- Sector
- Services-Prepackaged Software
- Headquarters
- Dover, DE
- Fiscal year end
- December 31
- Shares outstanding
- 26,723,870 [10-Q 2026-08-19]
What the company doesAI summary of filing
BiomX is a clinical-stage company developing phage-based therapeutic products designed to target harmful bacteria associated with chronic diseases. The company develops two types of phage therapies: fixed cocktail products containing selected phages to treat broad patient populations, and personalized therapies that match individual phages to specific patients. BiomX's lead programs target diabetic foot infections and diabetic foot osteomyelitis caused by Staphylococcus aureus, though the company discontinued development of its cystic fibrosis program (BX004) in December 2025 and subsequently faced material operational challenges including the insolvency of its Israeli subsidiary. The company has not generated any revenue from product sales and is in clinical development stages with ongoing support from the National Institutes of Health for a cystic fibrosis study. [10-K 2026-02-19]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $332.0K | −$22.99M | −$6.58M | $347.0K | [10-Q 2026-08-19] |
| FY ended Dec 2025 | — | −$36.20M | −$26.39M | $4.36M | [10-K 2026-02-19] |
| FY ended Dec 2024 | — | −$17.73M | −$36.98M | $16.86M | [10-K 2026-02-19] |
- Quarterly cash burn
- −$3.29M
- Cash runway Estimate
- ~0.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2025-03-20 | 24,966,053 | [10-K 2025-03-25] |
| 2025-05-11 | 26,176,311 | [10-Q 2025-05-15] |
| 2025-08-11 | 26,533,888 | [10-Q 2025-08-13] |
| 2025-11-11 | 29,006,165 | [10-Q 2025-11-12] |
| 2026-02-16 | 1,593,703 | [10-K 2026-02-19] |
| 2026-04-30 | 10,111,516 | [10-K/A 2026-04-30] |
| 2026-05-20 | 10,146,516 | [10-Q 2026-05-20] |
| 2026-08-18 | 26,723,870 | [10-Q 2026-08-19] |
- Shelf registration
- S-1 filed 2026-06-29; declared effective 2026-07-13 [S-1 2026-06-29]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-06-12. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-06-12 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-06-12] |
| 2026-03-27 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-27] |
| 2024-10-15 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-10-15] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-03-17 | Yeganeh Reuven | other | 530,000 | $2.00 | [4 2026-03-18] |
| 2026-03-17 | Yeganeh Reuven | sell | 530,000 | $5.00 | [4 2026-03-18] |
| 2026-03-16 | Yeganeh Reuven | other | 450,000 | $2.00 | [4 2026-03-18] |
| 2026-03-16 | Yeganeh Reuven | sell | 450,000 | $5.00 | [4 2026-03-18] |
| 2026-03-13 | Yeganeh Reuven | other | 370,000 | $2.00 | [4 2026-03-13] |
| 2026-03-13 | Yeganeh Reuven | sell | 370,000 | $5.00 | [4 2026-03-13] |
| 2026-03-12 | Yeganeh Reuven | sell | 300,000 | $5.00 | [4 2026-03-13] |
| 2026-03-11 | Yeganeh Reuven | other | 300,000 | $2.00 | [4 2026-03-13] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-07 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-10-06 | DEF 14A | Proxy statement |
| 2026-10-06 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-10-05 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-10-05 | 8-K | Material agreement entered; New financial obligation; Unregistered sale of equity |
| 2026-09-29 | 8-K | Regulation FD disclosure |
| 2026-09-25 | PRE 14A | Proxy statement |
| 2026-09-25 | 8-K | Material agreement entered |
| 2026-09-22 | 8-K | Material agreement entered; Unregistered sale of equity |
| 2026-09-17 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-09-15 | 8-K | Charter, bylaws or fiscal year change; Regulation FD disclosure |
| 2026-09-15 | 13D/A | Beneficial ownership report (5%+ holder) |
Alerts for $HLSQ
Email me when Tessera Defense & Homeland Security Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.